BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 28669337)

  • 1. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
    Gupta A; Ahmad A; Dar AI; Khan R
    Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
    Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
    Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Nanotechnology from Bench to Bedside.
    Sapalidis K; Kosmidis C; Laskou S; Katsaounis A; Mantalobas S; Passos I; Michalopoulos N; Amaniti A; Sardeli C; Zarogoulidis P
    Curr Cancer Drug Targets; 2019; 19(1):3-4. PubMed ID: 30672409
    [No Abstract]   [Full Text] [Related]  

  • 4. Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine.
    Jang SF; Liu WH; Song WS; Chiang KL; Ma HI; Kao CL; Chen MT
    Int J Mol Sci; 2014 Mar; 15(3):3904-25. PubMed ID: 24599081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology and nanomedicine: going small means aiming big.
    Teli MK; Mutalik S; Rajanikant GK
    Curr Pharm Des; 2010 Jun; 16(16):1882-92. PubMed ID: 20222866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy?
    Kateb B; Chiu K; Black KL; Yamamoto V; Khalsa B; Ljubimova JY; Ding H; Patil R; Portilla-Arias JA; Modo M; Moore DF; Farahani K; Okun MS; Prakash N; Neman J; Ahdoot D; Grundfest W; Nikzad S; Heiss JD
    Neuroimage; 2011 Jan; 54 Suppl 1(Suppl 1):S106-24. PubMed ID: 20149882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic lethality on drug discovery: an update on cancer therapy.
    Yar MS; Haider K; Gohel V; Siddiqui NA; Kamal A
    Expert Opin Drug Discov; 2020 Jul; 15(7):823-832. PubMed ID: 32228106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Double Strand Break Repair - Related Synthetic Lethality.
    Toma M; Skorski T; Sliwinski T
    Curr Med Chem; 2019; 26(8):1446-1482. PubMed ID: 29421999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia.
    Merajver S; Phadke S; Soellner M
    Trans Am Clin Climatol Assoc; 2017; 128():169-179. PubMed ID: 28790501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
    Srivas R; Shen JP; Yang CC; Sun SM; Li J; Gross AM; Jensen J; Licon K; Bojorquez-Gomez A; Klepper K; Huang J; Pekin D; Xu JL; Yeerna H; Sivaganesh V; Kollenstart L; van Attikum H; Aza-Blanc P; Sobol RW; Ideker T
    Mol Cell; 2016 Aug; 63(3):514-25. PubMed ID: 27453043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic lethal vulnerabilities of cancer.
    Fece de la Cruz F; Gapp BV; Nijman SM
    Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy.
    Jo SD; Ku SH; Won YY; Kim SH; Kwon IC
    Theranostics; 2016; 6(9):1362-77. PubMed ID: 27375785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine.
    Adir O; Poley M; Chen G; Froim S; Krinsky N; Shklover J; Shainsky-Roitman J; Lammers T; Schroeder A
    Adv Mater; 2020 Apr; 32(13):e1901989. PubMed ID: 31286573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology.
    Hauert S; Bhatia SN
    Trends Biotechnol; 2014 Sep; 32(9):448-55. PubMed ID: 25086728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic lethality: a step forward for personalized medicine in cancer.
    Jariyal H; Weinberg F; Achreja A; Nagarath D; Srivastava A
    Drug Discov Today; 2020 Feb; 25(2):305-320. PubMed ID: 31811941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision gas therapy using intelligent nanomedicine.
    He Q
    Biomater Sci; 2017 Oct; 5(11):2226-2230. PubMed ID: 28937694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora kinase A, a synthetic lethal target for precision cancer medicine.
    Mou PK; Yang EJ; Shi C; Ren G; Tao S; Shim JS
    Exp Mol Med; 2021 May; 53(5):835-847. PubMed ID: 34050264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic lethality: emerging targets and opportunities in melanoma.
    Thompson N; Adams DJ; Ranzani M
    Pigment Cell Melanoma Res; 2017 Mar; 30(2):183-193. PubMed ID: 28097822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.